Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 40 for:    "umbilical cord mesenchymal stem cells" | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies

Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04074408
Recruitment Status : Not yet recruiting
First Posted : August 30, 2019
Last Update Posted : August 30, 2019
Sponsor:
Collaborators:
The First Affiliated Hospital, University of Science and Technology of China
Huzhou Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital of Fujian Medical University
Jinhua Hospital, School of Medicine, Zhejiang University
Taizhou Hospital
Information provided by (Responsible Party):
Second Affiliated Hospital, School of Medicine, Zhejiang University

Tracking Information
First Submitted Date  ICMJE August 26, 2019
First Posted Date  ICMJE August 30, 2019
Last Update Posted Date August 30, 2019
Estimated Study Start Date  ICMJE December 2019
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 28, 2019)
  • Frequency of dose limiting adverse events [ Time Frame: 3 days ]
  • Modified Rankin Scale (mRS) to measure the prognosis [ Time Frame: 3 months ]
    The Modified Rankin Scale (mRS) measures independence rather than performance of specific tasks. Scale consists of six grades from 0 to 5; 0 denotes no symptoms and 5 indicates severe disability. For clinical purpose, mild disability range is from 0 to 2; moderate disability ranges from 3 to 4 and 5 indicates severe disability.
  • National institute of Health Stroke Scale (NIHSS) to measure stroke recovery [ Time Frame: 3 months ]
    The National Institutes of Health Stroke Scale (NIHSS) is a 15-item impairment scale used to measure stroke severity. The NIHSS includes the following domains: level of consciousness, eye movements, integrity of visual fields, facial movements, arm and leg muscle strength, sensation, coordination, language, speech and neglect. Each impairment is scored on an ordinal scale ranging from 0 to 2, 0 to 3, or 0 to 4. Item scores are summed to a total score ranging from 0 to 42 (the higher the score, the more severe the stroke).
  • Barthel Index (BI) to evaluate the self-care ability [ Time Frame: 3 months ]
    The Barthel index (BI) is an ordinal scale used to measure performance in activities of daily living (ADL). It uses ten variables describing ADL and mobility including: help needed with grooming, toilet use, feeding, transfers, walking, dressing, climbing stairs, bathing, presence of absence of fecal incontinence and urinary incontinence. Each performance item is rated on this scale with a given number of points from 0 to 10 or 0 to 15. Item scores are summed to a total score ranging from 0 to 100. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence. Totally dependent ranges from 0 to 20, severe dependent ranges from 21 to 60, moderate dependent ranges from 61 to 90, mild dependent ranges from 91 to 99, and 100 indicates completely independent.
  • Rate of muscle strength level of the hemiplegic limb [ Time Frame: 3 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: August 28, 2019)
  • Mortality rate [ Time Frame: 12 months ]
  • Change in Glasgow coma scale (GCS) score [ Time Frame: 1 month ]
    The Glasgow coma scale (GCS) is based on a 15-point scale for estimating and categorizing the consciousness. The test measures the motor response (1 to 6), verbal response (1 to 5) and eye opening response (1 to 4). The score is determined by the sum of the score in each of the 3 categories, with a maximum score of 15 and a minimum score of 3. A lower number indicating a more severe injury and a poorer prognosis.
  • Change in Glasgow outcome scale (GOS) score [ Time Frame: 12 months ]
    The Glasgow outcome score (GOS) applies to patients with brain damage allowing the objective assessment of their recovery. This allows a prediction of the long-term course of rehabilitation to return to work and everyday life. Scale consists of five grades from 1 to 5. 1 denotes death. 2 denotes persistent vegetative state.3 denotes severe disability. 4 denotes moderate disability and 5 denotes low disability.
  • MRI (T1, T2, Flair, DWI) scanning [ Time Frame: 12 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration
Official Title  ICMJE Intracavitary Injection of Human Umbilical Cord Mesenchymal Stem Cells in Acute Basal Ganglia Hematoma After Stereotactic Aspiration: a Randomized, Single-blind, Placebo-Controlled, Phase 2 Trial
Brief Summary A study to examine the safety and potential effectiveness of human umbilical cord mesenchymal stem cells (hUMSCs) in adults who have suffered spontaneous cerebral hemorrhage in basal ganglia. The hypothesis is that hUMSCs will be safe and can improve neurological function after intracerebral hemorrhage so that improve the prognosis of patients.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Masking Description:
The hUMSCs suspension and placebo solvent have different appearance so only the participants but not the researches can be masked.
Primary Purpose: Treatment
Condition  ICMJE Basal Ganglia Hematoma
Intervention  ICMJE
  • Procedure: stereotactic surgery
    stereotactic aspiration surgery
  • Biological: hUMSCs
    single intracavitary infusion 1 day after stereotactic aspiration surgery
  • Biological: placebo
    single intracavitary infusion 1 day after stereotactic aspiration surgery
Study Arms  ICMJE
  • Experimental: Cohort 1
    low dose hUMSCs or high dose hUMSCs
    Interventions:
    • Procedure: stereotactic surgery
    • Biological: hUMSCs
  • Experimental: Cohort 2
    best dose of hUMSCs (from cohort 1) or placebo
    Interventions:
    • Procedure: stereotactic surgery
    • Biological: hUMSCs
    • Biological: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: August 28, 2019)
100
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2023
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female participants between 30 and 75 years of age, diagnosed of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a volume from 30 ml to 50 ml calculated by ABC/2 formula.
  • Within 5 days from onset to operation, and no improvement.
  • Glasgow Coma Scale (GCS) score of 5 to 15.
  • With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength≤grade 3.
  • Modified Rankin scale (mRS) score≤1 in past medical history.
  • Women of reproductive age have negative pregnancy tests.
  • The participants or the legal guardian/representative who are suitable and willing to participate in the clinical trial and can cooperate to complete the follow-ups.

Exclusion Criteria:

  • Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation AVM and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage.
  • In the sequela stage of cerebral trauma.
  • Hematoma involves other structures including but not limited to the thalamus and midbrain or complicated with intraventricular hemorrhage.
  • With neurologic impairment before cerebral hemorrhage onset.
  • Participants receiving anticoagulant or antiplatelet therapy.
  • The disease progresses quickly. Manifestation of cerebral herniation such as bilateral dilated pupil, disappearance of light reflex, and unstable vital signs.
  • Active stage of infectious diseases including but not limited to HIV, hepatitis B, and C.
  • History of poorly controlled seizures.
  • History of severe co-morbidity (including but not limited to hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which may affect the outcome assessment. Coagulation dysfunction INR >1.4, PTT>37 seconds, thrombocytopenia (PLT<8×10^9/L), serum creatinine exceeded the upper limit of normal by 1.4 times, serum ALT >150U/L, and/or serum total bilirubin >1.6mg/dl.
  • Participants with a mechanical heart valve. Biological valves are acceptable.
  • Participants with a risk of embolism (including but not limited to a history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is acceptable.
  • May be pregnant in the near future or already pregnant.
  • Enrolled in this clinical trial or participating in other interventional medical research or clinical trials at the same time.
  • Participants difficult to follow up or with poor compliance due to various reasons (including but not limited to geographical and social factors, drug or alcohol abuse).
  • Participants or the legal guardian/representative is unable or unwilling to give the written informed consent.
  • Vulnerable groups (including but not limited to mental retardation, abuse, inability to fully exercise informed consent).
  • Any subject that the researchers think is not suitable for enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 30 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jianmin Zhang, Doctor 86-13805722695 2307010@zju.edu.cn
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04074408
Other Study ID Numbers  ICMJE SAHZJU-hUMSCs
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Sponsor  ICMJE Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators  ICMJE
  • The First Affiliated Hospital, University of Science and Technology of China
  • Huzhou Hospital, School of Medicine, Zhejiang University
  • First Affiliated Hospital of Fujian Medical University
  • Jinhua Hospital, School of Medicine, Zhejiang University
  • Taizhou Hospital
Investigators  ICMJE Not Provided
PRS Account Second Affiliated Hospital, School of Medicine, Zhejiang University
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP